LOGC vs. MYTE, BWMX, VGII, OGBLY, OG, ODP, BBW, CARS, BH, and ETD
Should you be buying LogicBio Therapeutics stock or one of its competitors? The main competitors of LogicBio Therapeutics include MYT Netherlands Parent B.V. (MYTE), Betterware de México, S.A.P.I. de C.V. (BWMX), Virgin Group Acquisition Corp. II (VGII), Onion Global (OGBLY), Onion Global (OG), ODP (ODP), Build-A-Bear Workshop (BBW), Cars.com (CARS), Biglari (BH), and Ethan Allen Interiors (ETD).
LogicBio Therapeutics vs. Its Competitors
MYT Netherlands Parent B.V. (NYSE:MYTE) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.
MYT Netherlands Parent B.V. presently has a consensus price target of $14.00, suggesting a potential upside of 80.65%. Given MYT Netherlands Parent B.V.'s stronger consensus rating and higher probable upside, equities research analysts clearly believe MYT Netherlands Parent B.V. is more favorable than LogicBio Therapeutics.
MYT Netherlands Parent B.V. has higher revenue and earnings than LogicBio Therapeutics. MYT Netherlands Parent B.V. is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks.
MYT Netherlands Parent B.V. has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 2.06, indicating that its share price is 106% more volatile than the S&P 500.
In the previous week, MYT Netherlands Parent B.V.'s average media sentiment score of 0.00 equaled LogicBio Therapeutics'average media sentiment score.
10.1% of MYT Netherlands Parent B.V. shares are held by institutional investors. Comparatively, 46.1% of LogicBio Therapeutics shares are held by institutional investors. 1.9% of MYT Netherlands Parent B.V. shares are held by insiders. Comparatively, 8.1% of LogicBio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
MYT Netherlands Parent B.V. has a net margin of -3.98% compared to LogicBio Therapeutics' net margin of -141.03%. MYT Netherlands Parent B.V.'s return on equity of -5.88% beat LogicBio Therapeutics' return on equity.
Summary
MYT Netherlands Parent B.V. beats LogicBio Therapeutics on 10 of the 14 factors compared between the two stocks.
Get LogicBio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LOGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LogicBio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LOGC) was last updated on 10/13/2025 by MarketBeat.com Staff
